These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31759907)

  • 1. CFTR: New insights into structure and function and implications for modulation by small molecules.
    Kleizen B; Hunt JF; Callebaut I; Hwang TC; Sermet-Gaudelus I; Hafkemeyer S; Sheppard DN
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S19-S24. PubMed ID: 31759907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
    Cai ZW; Liu J; Li HY; Sheppard DN
    Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
    Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
    J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting species differences to understand the CFTR Cl- channel.
    Bose SJ; Scott-Ward TS; Cai Z; Sheppard DN
    Biochem Soc Trans; 2015 Oct; 43(5):975-82. PubMed ID: 26517912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Approaches for Potential Therapy of Cystic Fibrosis.
    Sawczak V; Getsy P; Zaidi A; Sun F; Zaman K; Gaston B
    Curr Drug Targets; 2015; 16(9):923-36. PubMed ID: 25557257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
    Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
    Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
    Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
    J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
    Kim Chiaw P; Eckford PD; Bear CE
    Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
    Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations.
    Csanády L; Töröcsik B
    Elife; 2019 Jun; 8():. PubMed ID: 31205003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
    Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
    J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
    Strub MD; McCray PB
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CFTR ion channel: gating, regulation, and anion permeation.
    Hwang TC; Kirk KL
    Cold Spring Harb Perspect Med; 2013 Jan; 3(1):a009498. PubMed ID: 23284076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.